University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 13 Trials 
30 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sloan, Andrew E
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
TVI-AST-008, NCT05685004: Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Recruiting
2/3
120
US
TVI-Brain-1, Standard of Care, Radiotherapy, Temozolomide, Chemotherapy
TVAX Biomedical
Glioblastoma Multiforme of Brain
12/26
03/27
hSTAR GBM, NCT05052957: (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Recruiting
2
16
US
P140K-MGMT, O6-benzylguanine, BG, Photon Based Radiotherapy, temozolomide, TMZ, Filgrastim, G-CSF,Granulocyte-Colony Stimulating Factor, carmustine, BCNU,bis-chloronitrosourea
Leland Metheny, National Cancer Institute (NCI)
Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
06/25
12/25
ImmuneSense, NCT04485949: A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Active, not recruiting
2
93
US
IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide
Imvax
Glioblastoma
01/25
07/27
NCT01269424: BG & TMZ Therapy of Glioblastoma Multiforme

Completed
1
10
US
MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy
Stanton Gerson MD, National Cancer Institute (NCI)
Glioblastoma Multiforme
12/20
09/22
Caimi, Paolo
NCT02588651: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Active, not recruiting
2
23
US
Brentuximab vedotin
Deepa Jagadeesh
T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepato-splenic T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma, Enteropathy Associated T-cell Lymphoma, NK T-cell Lymphoma
12/24
12/27
ALPHA3, NCT06500273: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting
2
250
US
cemacabtagene ansegedleucel, cema-cel, ALLO-647, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, Foresight Lymphoma MRD Therapy Selection Test
Allogene Therapeutics, Foresight Diagnostics, Inc.
Large B-cell Lymphoma
08/27
08/31
EA4181, NCT04115631: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting
2
360
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Bendamustine, SDX-105, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Liver Lymphoma, Mantle Cell Lymphoma
12/25
12/25
PRO1160-001, NCT05721222: PRO1160 for Advanced Solid and Liquid Tumors

Recruiting
1/2
134
US, RoW
PRO1160
ProfoundBio US Co.
Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma
11/26
03/27
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
NCT03921879: Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

Recruiting
1
50
US
OT-82 Dose Escalation, OT-82 Dose Expansion
Oncotartis, Inc.
Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Follicular, Lymphoma, Peripheral T-Cell, Lymphoma, Hodgkin
04/21
06/21
NCT05053659: Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Recruiting
1
36
US
Loncastuximab tesirine, ADCT-402, lonca, Venetoclax, ABT-199, GDC-0199
Paolo Caimi, MD
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
06/25
12/25
CASE2422, NCT05400109: Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

Recruiting
1
16
US
UF-KURE19 CAR-T cells, Fludarabine, Fludara®, Fludarabine Phosphate, Cyclophosphamide, Cytoxan ®, Endoxan®, Neosar®, Procytox®, Revimmune®, Cycloblastin®
Changchun Deng, MD
Non Hodgkin Lymphoma
04/25
10/25
LMY-920-001, NCT05312801: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

Recruiting
1
20
US
BAFF CAR-T, LMY-920
Luminary Therapeutics, Case Comprehensive Cancer Center
Lymphoma, Non-Hodgkin Lymphoma, B-Cell
05/25
09/25
NCT06447376: Study of Cytokine Release Syndrome Prophylaxis and Treatment with Siltuximab Prior to Epcoritamab

Recruiting
1
20
US
Siltuximab, Epcoritamab
Paolo Caimi, MD, Genmab, AbbVie, Recordati Rare Diseases
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
09/28
09/28
Dallas, Mari H
NCI-2018-01752, NCT03779854: Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Recruiting
2
68
US
Total-Body Irradiation, Total Body Irradiation, Whole-Body Irradiation, SCT_TBI, TBI, Whole Body Irradiation, Thiotepa, 1,1',1"-phosphinothioylidynetrisaziridine, Oncotiotepa, STEPA, Tepadina, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoramide, triethylenethiophosphoramide, Fludarabine, 2-Fluoro-9-beta-arabinofuranosyladenine, 2-Fluorovidarabine, Fluradosa, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, Cycloblastin, Cytophosphane, Busulfan, Bussulfam, Busulfanum, Busulfex, Busulphan, Misulban, Misulfan, Mitosan, Myeleukon, Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic Blood and Marrow Transplantation, Allogeneic BMT, Tacrolimus, Fujimycin, Hecoria, Prograf, Protopic, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, Emtexate, Emthexat, Emthexate, Farmitrexat, Medsatrexate, Methoblastin, Rheumatrex, Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation, Echocardiography, EC, ECHO, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blasts Under 25 Percent of Bone Marrow Nucleated Cells, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Burkitt Leukemia, Chronic Monocytic Leukemia, Lymphoblastic Lymphoma, Mast Cell Leukemia, Myeloproliferative Neoplasm
12/25
12/25
NCT02982902: T Cell Therapy of Opportunistic Cytomegalovirus Infection

Recruiting
1
20
US
CMV specific adoptive t-cells, immunotherapy
Mari Dallas
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplant, Opportunistic Infections
08/27
08/28
NCT03378102: Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

Recruiting
1
20
US
IFN-gamma-secreting HAdV antigen specific T cells, Antigen-selected, adenovirus-specific T Cells
Mari Dallas
Allogeneic Hematopoietic Stem Cell Transplantation
12/28
12/28
NCT06421155: Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia

Not yet recruiting
N/A
20
US
MRF with neurocognative studies
Case Comprehensive Cancer Center
Acute Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Acute Myeloid Leukemia in Children, Myeloproliferative Neoplasm
06/27
06/28
Bajor, David
A021806, NCT04340141: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Recruiting
3
352
Canada, US
Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
01/26
11/30
NCT02861300: CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Completed
1/2
50
US
CB-839, Capecitabine, Xeloda
David Bajor, MD
Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
01/23
01/23
NCT03699319: CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Completed
1/2
49
US
CPI 613, 6, 8-bis-benzylsulfanyloctanoic acid, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, 5-flurouracil, 5FU, Folinic acid, Leucovorin, Calcium folinate, FA
David Bajor, MD
Pancreatic Cancer
09/24
09/24
BilT-04, NCT04203160: Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer

Completed
1/2
75
US
CPI 613, Devimistat®, Gemcitabine, Gemzar®, Cisplatin, CDDP, Platinol®, NSC-119875
University of Michigan Rogel Cancer Center
Biliary Tract Cancer
04/24
04/24
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT05209074: Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Recruiting
1
16
US
Ivosidenib, mFOLFIRINOX
Case Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
07/26
12/26
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults with Select Solid Tumors

Recruiting
1
241
Europe, US
TOS-358
Totus Medicines
Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer
12/25
12/25
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
SGNEGFRd2-001, NCT05983133: A Study of SGN-EGFRd2 in Advanced Solid Tumors

Recruiting
1
275
Europe, US
SGN-EGFRd2
Seagen Inc.
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
07/27
09/28
NCT05238467: Immunological Responses of COVID-19 Vaccination

Completed
N/A
42
US
COVID antibody titers in the blood
University Hospitals Cleveland Medical Center
Cancer; Chemotherapy
02/23
02/23

Download Options